Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.03

€1.03

-3.740%
-0.04
-3.740%
-
 
17:20 / Tradegate WKN: A41GYL / Name: Mindwalk Holdings Corp. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Mindwalk Holdings Corp. Stock

Mindwalk Holdings Corp. took a tumble today and lost -€0.040 (-3.740%).

Pros and Cons of Mindwalk Holdings Corp. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

MindWalk Announces B Cell Llama(TM), a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
MindWalk Announces B Cell Llama(TM), a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right

MindWalk Applies HYFT® to Detect Functional Adjacency Risk in AI-Designed Therapeutics
MindWalk Applies HYFT® to Detect Functional Adjacency Risk in AI-Designed Therapeutics

AUSTIN, Texas – MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

14 January 2026 – VICTORIA, British Columbia – MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and